BHVN
BiohavenBNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-27
Current thesis
Multiple second-half 2026 clinical milestones, completed obesity enrollment, and potential pivotal starts across the degrader platform provide meaningful value inflection opportunities.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -0.9.
What can break
Binary clinical readout failure or delay in opakalim or taldefgrobep.
Momentum
97
Value
41
Sentiment
51
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $14.00 · Bull $24.00 · Bear $9.00
Data freshness
Prices
As of 2026-07-27
Fundamentals
As of 2026-07-27 • Vendor: Data Vendor v1
Scores
As of 2026-07-27 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-27
Investment thesis
As of 2026-07-27
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $22.93
Why
Momentum97 · Δ7d -0.9
Value41 · Δ7d 0.0
Sentiment51 · Δ7d +5.5
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
97
26% active weight
Current posture
7d trendFlat
Δ7d
-0.9
Δ21d
+1.6
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
-0.1
Sentiment
51
34% active weight
Current posture
7d trendImproving
Δ7d
+5.5
Δ21d
-19.2
Why this grade
Composite grade B. Momentum 97.2 / Value 41.1 / Sentiment 51.0
Fundamentals (TTM)As of 2026-07-27
Fundamentals (TTM)
As of 2026-07-27
Market Cap
$2.18B
Beta
3.56
Shares Out
150.56M
P/E (TTM) · Derived
-2.1
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.83
Rev YoY
-
EPS YoY
-59.3%
Gross Margin
-
Op Margin
-
Net Debt
-$35.3M
Current Ratio
7.41
As of 2026-07-27 • Updated nightlySource: Internal modelMethodology